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2014, 251 EU5 gastroenterologists were surveyed regarding their perceptions and 
uptake of sofosbuvir. Additionally, 15 reimbursement-influencing payers were 
interviewed. RESULTS: At the time of surveying, approximately one-quarter of 
treatment-naïve cirrhotic and non-cirrhotic HCV-1 patients in France and Germany 
(where sofosbuvir was then widely available) were on sofosbuvir-based regimens, 
alongside a slightly lower percentage of treatment-experienced such patients, and 
those with HCV-2/3. This speedy uptake reflects sofosbuvir’s high efficacy, which 
previously encouraged physician familiarity via early-access schemes. However, 
interviewed payers insist sustained uptake for large HCV patient populations is 
not viable due to cost, stressing that sofosbuvir be reserved for patients with more 
advanced liver fibrosis or cirrhosis. These payers add that measures such as those 
in France involving treatment caps and a proposal to tax manufacturers when caps 
are exceeded exemplify the innovative cost-containment strategies necessary to 
manage the burden of sofosbuvir. CONCLUSIONS: The EU5 healthcare authorities 
have adapted to include sofosbuvir within their budgets. As indicated by our primary 
research, and confirmed since, creative cost-containment is the order of the day 
across the EU5 for sofosbuvir, with payers forced to reexamine their traditional P&R 
schemes and reevaluate how they define cost-effectiveness. However, such aggres-
sive cost-containment measures have consequences, as demonstrated when thou-
sands took to the streets in Spain in January, 2015, protesting for fairer allocation 
of HCV treatment. Manufacturers of such premium-priced agents may learn from 
Janssen’s negotiations on simeprevir, which offered trade-offs using teleprevir, as 
careful balancing of long-range price expectations and reimbursement and uptake 
potential will be required going forward.
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OBJECTIVES: Misbeliefs regarding vaccine safety and strict immunization exemp-
tion policy have led to anti-vaccination sentiments in West Virginia which might 
affect the vaccination of children. This study assessed the levels of worry and 
hassles towards vaccination and their association with up-to-date vaccination 
status and future intentions to follow recommended vaccinations. METHODS: A 
cross-sectional online survey was conducted among 176 mothers of children under 
3 years old in West Virginia who could read and understand English. Worry and 
hassles scales were developed, and mean scale scores were used to measure worry 
and hassles to vaccination. Chi-square, t-tests and logistic regression analyses 
were conducted. RESULTS: Participants were predominantly white (94.3%), non-
Hispanic Appalachians (98.3%), with annual household income > $50,000 (72.6%) 
and health insurance (92.0%). Approximately 3.8% of participants’ children had not 
received any vaccination. Further, many participants’ children (14.2%) were not up 
to date with recommended vaccinations, and 13.6% of mothers reported no future 
intention to follow recommended vaccination. Chi-square analyses indicated that 
being a full time worker and self or family as child caretaker were associated with 
being up-to-date with recommended vaccination and future intention to follow 
recommended vaccinations (p’s< 0.05). After adjusting for demographic variables, 
hassle scale was a significant predictor of up-to-date vaccination status (AOR 
= 0.12) and future intention to follow recommended vaccinations (AOR = 0.17). 
Similarly, worry scale was a significant predictor of up-to-date vaccination status 
(AOR = 0.24) and future intention to follow recommended vaccinations (AOR = 
0.27). CONCLUSIONS: Despite having higher socio-economic status, many study 
participants’ children exhibited low immunization coverage, and had no future 
intention to follow recommended vaccination. The study highlights the need to 
increase awareness about safety of vaccine contents and its efficacy in preventing 
still endemic diseases like measles.
PIN93
eNcouragINg orPhaN desIgNatIoN for New ebola treatmeNts – could 
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OBJECTIVES: The current Ebola Virus outbreak has been responsible for over 5,000 
deaths. This disease, with no effective treatment has a fatality rate around 50%. 
In October, the EMA publically encouraged developers of Ebola treatments and 
vaccines to apply for orphan designation and FDA have already granted orphan 
designation for ZMapp. This research aimed to evaluate the appropriateness of 
utilising the orphan designation as an incentive in these circumstances or whether 
it could actually prove counter-productive. METHODS: A detailed review of EMA and 
FDA orphan designation procedures and the historical context in which they were 
developed were undertaken, alongside a review of the current Ebola treatment and 
vaccinations pipeline. RESULTS: EMA and FDA orphan drug legislation comprise a 
set of incentives for pharmaceutical companies to develop and market medicinal 
products to treat rare diseases, which were being neglected by drug developers due 
to the poor economic potential of such diseases. These include scientific advice, 
fee reductions, access to grants and, most importantly, market exclusivity (7 and 
10 years for the FDA and EMA respectively). However, in contrast to most orphan 
diseases with a lack of pipeline candidates, there are already 7 pipeline drugs for 
Ebola (brincidofovir, favipiravir, ZMapp, TKM-Ebola, AVI-4753, hyperimmune horse 
sera, and BCX4430) and 2 vaccines (ChAd 3, VSV-EBOV). CONCLUSIONS: Granting 
orphan status to pipeline Ebola candidates means that the first-to-market will attain 
market exclusivity in that jurisdiction, such that any later candidates, even if clearly 
more effective, will be prevented from launching until the data exclusivity period 
has expired. This could not only potentially deny Ebola patients in US and Europe 
access to the most efficacious treatments but could also disincentivize companies 
developing potentially more effective therapies. We recommend that the market 
exclusivity aspect of the orphan drug designation should be waived for candidate 
Ebola treatments.
for PILLAR, QUEST-1 and QUEST-2, respectively. Having VR only had a minor posi-
tive impact, and was not statistically significant for most endpoints/trials. Female 
patients had significantly lower values for EQ-5D-VI, and numerically lower values 
for all other QoL-measures. CONCLUSIONS: These findings suggest that short-
term QoL impairment due to HCV-therapy is driven more by the longer duration of 
PR-therapy than by not obtaining VR.
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OBJECTIVES: Limited Patient Reported Outcomes (PRO) data exists for obese 
patients with ABSSSI. This study sought to evaluate health-related quality of life 
(HRQL) in obese patients (BMI > 30) with a positive clinical response (cured, com-
plete resolution of all baseline signs and symptoms and improved, some symp-
toms remain, but no further antibiotics are necessary) patients during an ABSSSI 
trial. METHODS: Adult patients diagnosed with ABSSSI were enrolled in a pro-
spective phase 3, randomized, double-blind study to evaluate antibiotic treatment. 
An analysis of PRO was conducted to understand the difference between cured 
obese patients (COP) and improved obese patients (IOP) with respect to patient 
reported HRQL at End of Treatment (EOT) and late follow up (LFU, study day 21-28). 
HRQL was measured by Extremity Soft Tissue Infection (ESTI) Score[i], a 20 ques-
tion survey using a 5-point Likert scale (5 equals highest degree of importance/
impairment to the patients) measured symptoms, daily functioning, emotional 
functioning, and social interactions. RESULTS: Obese patients compromised 29% 
of the study (660 patients, 589 included in analysis, 193 obese). IOP at EOT were 
less likely to proceed to cure than non-obese patients (26%, 16%) at LFU. The ESTI 
Score was higher at LFU in IOP than COP (46.4, 26.3, p= 0.029). At LFU, IOP were 
more likely than COP to report having continued difficulty performing a job (29.0%, 
9.6%, p= 0.008) and earning an income (32.3%, 14.0%, p= 0.032). CONCLUSIONS: IOP 
had more difficulty than COP with HRQL measures at LFU. IOP at EOT may have 
persistent HRQL issues that require further utilization of health care resources. 
Additional research is needed to determine the potential economic impact of this 
data. [i] Storck et al, Development of a Health-Related Quality of Life Questionnaire 
(HRQL) for patients with Extremity Soft Tissue Infections (ESTI), BMC Infectious 
Diseases 2006, 6:148
INfectIoN – health care use & PolIcy studIes
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OBJECTIVES: The FDA plans to institute a novel regulatory pathway to expedite 
approval of high-need antibiotics, including those for multidrug-resistant gram-
negative pathogens (MDR GNPs). Under this Limited Population Antibacterial Drugs 
(LPAD) approval mechanism, submission of clinical efficacy data from relatively 
small patient populations with high unmet need would be permitted. However, 
drugs approved via this pathway will have limited safety data and likely carry sig-
nificant price premiums over standard-of-care. This study assessed potential mar-
ket access hurdles for LPAD pathway-approved agents providing improvements in 
clinical cure rates, mortality rates and/or length of hospital/ICU stay for infections 
caused by MDR GNPs. METHODS: A total of 30 U.S. hospital pharmacy directors (PDs) 
and 141 U.S hospital-based infectious disease (ID) and non-ID specialists were sur-
veyed regarding their views on reimbursement and likely uptake of LPAD pathway-
approved drugs, assuming these agents cost ≥ $15,000/treatment course. RESULTS: 
Among surveyed physicians and PDs, < 25% and < 50%, respectively, were aware of 
the proposed LPAD pathway. Based on a short explanation, 87% of surveyed PDs 
would include LPAD pathway-approved agents. Among these PDs, 96% would imple-
ment prescribing restrictions on top of those included in the product label, although 
only 27% indicated they would restrict these agents to last-line therapy. Among 
physician respondents, 84% reported that they would use formulary-included LPAD 
pathway-approved agents providing improvements over standard-of-care, with 
agents demonstrating lower mortality rates relative to comparators more likely to 
see uptake. Furthermore, surveyed physicians who would use an LPAD pathway-
approved agent are most likely to do so for the same infections and drug-resistant 
pathogens evaluated during the LPAD process. CONCLUSIONS: Physicians and pay-
ers are receptive to LPAD pathway-approved agents despite potential for safety risks 
and high price premiums. However, prescribing restrictions and price limitations 
are certain among payers, while primary prescribing drivers are improvements in 
clinical cure and mortality rates.
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OBJECTIVES: Sofosbuvir is an indispensable innovation in hepatitis C virus (HCV) 
treatment. However, it has the potential to bust tight EU5 healthcare budgets. 
This study examined early uptake of sofosbuvir, and explored evolving mecha-
nisms in the EU5 used to manage its high cost burden. METHODS: In September 
